Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
basiliximab + mycophenolate sodium + everolimus + prednisolone
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This therapeutic regimen is a de-novo calcineurin-inhibitor (CNI)-free immunosuppressive protocol designed for liver transplant recipients, particularly those presenting with impaired renal function at the time of surgery. The regimen, evaluated in the Phase II CILT trial led by Armin Goralczyk, consists of induction therapy with basiliximab (a chimeric monoclonal antibody targeting the IL-2 receptor alpha chain) followed by a maintenance combination of mycophenolate sodium (an IMPDH inhibitor), everolimus (an mTOR inhibitor), and prednisolone (a corticosteroid). By eliminating CNIs such as tacrolimus or cyclosporine, which are associated with significant nephrotoxicity, the regimen aims to preserve renal function while maintaining effective prophylaxis against acute organ rejection.
- Brand names
- Simulect + Myfortic + Certican
- Other names
- CNI-free immunosuppressive regimenbasiliximab + EC-MPS + everolimus + prednisolone
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)GR (Glucocorticoid receptor)mTOR (Mammalian target of rapamycin kinase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on basiliximab + mycophenolate sodium + everolimus + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on basiliximab + mycophenolate sodium + everolimus + prednisolone.